https://www.statnews.com/2022/01/21/ibm-watson-health-sale-equity/ Skip to Main Content STAT * * * Contribute * Subscribe * Log In Try STAT+ Today My Account * My Account * Billing * Log Out Try STAT+ Today My Account [ ] Search Cancel * TOPICS + Coronavirus + Health + Pharma + Biotech + Politics & Policy + Health Tech + In the Lab + Business + Artificial Intelligence + Vaccines + Health Disparities + Prescription Politics * OPINION + First Opinion + The Pharmalot View + Adam's Take + Matt's Take + Off the Charts * TEAM + Biotech & Pharma o Adam Feuerstein o Damian Garde o Matthew Herper o Meghana Keshavan o Kate Sheridan o Ed Silverman o Jonathan Wosen + Health Tech o Mario Aguilar o Katie Palmer o Mohana Ravindranath o Casey Ross + Politics o Rachel Cohrs o Lev Facher o Nicholas Florko + Health & Science o Eric Boodman o Helen Branswell o Angus Chen o Elizabeth Cooney o Isabella Cueto o Olivia Goldhill o Andrew Joseph o Megan Molteni o Usha Lee McFarling o Jennifer Adaeze Okwerekwu o Nicholas St. Fleur + Team o View All * EVENTS + STAT Events + 2022 STAT Breakthrough Science Summit + Industry Events Calendar + View all Summits + Webinars * NEWSLETTERS * REPORTS * VIDEO * PODCASTS + The Readout LOUD + First Opinion Podcast * * STAT+ + STAT+ Exclusive analysis of biotech, pharma, and the life sciences Learn More o The Latest o My Account + Topics o Biotech o Pharma o Policy o Health Tech o Business + Columns o Adam's Take o Matt's Take o The Pharmalot View + Tools o CRISPR Tracker o Drug Pricing Policy Cheat Sheet + Events o STAT+ Conversations o All STAT Events + Team o Biotech and Pharma o Health Tech o Politics and Policy o Health and Science Account * My Account * Billing * Subscribe * Log In * Help More * Contribute * Group Subscriptions Follow Us * * * * * Trending: First Opinion Coronavirus Health Biotech STAT+ Subscribe Now To access exclusive content, subscribe to STAT+ View Latest View the latest STAT+ stories [stat-plus-] In-depth analysis of biotech, pharma, and the life sciences * [journalism] Award-winning journalism from some of the nation's most trusted and well-connected reporters in the industry * [video-chat] Weekly live video chats with STAT+ reporters and leading industry experts in our STAT+ Conversations series * [events] Exclusive industry events hosted by STAT+, plus early-bird access and discounts to industry events around the country * [newsletter] Daily STAT+ newsletters get delivered to your inbox to brief you on the most important industry news of the day * [data-tools] Premium data tools like our CRISPR Trackr and Drug Pricing Policy Tracker Exclusive coverage and analysis of BIOTECH, PHARMA, AND THE LIFE SCIENCES Try STAT+ 30 days FREE Learn More [stat-plus-] In-depth analysis of biotech, pharma, and the life sciences * [journalism] Award-winning journalism from some of the nation's most trusted and well-connected reporters in the industry * [video-chat] Weekly live video chats with STAT+ reporters and leading industry experts in our STAT+ Conversations series * [events] Exclusive industry events hosted by STAT+, plus early-bird access and discounts to industry events around the country * [newsletter] Daily STAT+ newsletters get delivered to your inbox to brief you on the most important industry news of the day * [data-tools] Premium data tools like our CRISPR Trackr and Drug Pricing Policy Tracker Exclusive coverage and analysis of BIOTECH, PHARMA, AND THE LIFE SCIENCES Try STAT+ 30 days FREE Learn More Health Tech STAT+ Once billed as a revolution in medicine, IBM's Watson Health is sold off in parts * Casey Ross By Casey Ross Jan. 21, 2022 Reprints * * * * * * * * * Fall of Watson Hyacinth Empinado/STAT; Eros Dervishi for STAT * * * * * * * * * IBM said Friday it will sell the core data assets of its Watson Health division to a San Francisco-based private equity firm, marking the staggering collapse of its ambitious artificial intelligence effort that failed to live up to its promises to transform everything from drug discovery to cancer care. Data and analytics assets held by the health business, which was not profitable, were sold to Francisco Partners as IBM seeks to refocus its business on cloud computing and AI services to help clients in multiple industries build machine learning tools and secure and manage their data. Terms of the transaction were not disclosed. [stat-plus-] Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Log In | Learn More What is it? STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What's included? * Daily reporting and analysis * The most comprehensive industry coverage from a powerhouse team of reporters * Subscriber-only newsletters * Daily newsletters to brief you on the most important industry news of the day * STAT+ Conversations * Weekly opportunities to engage with our reporters and leading industry experts in live video conversations * Exclusive industry events * Premium access to subscriber-only networking events around the country * The best reporters in the industry * The most trusted and well-connected newsroom in the health care industry * And much more * Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. GET STARTED * * * * * * * * * About the Author Reprints Casey Ross Casey Ross National Technology Correspondent Casey covers the use of artificial intelligence in medicine and its underlying questions of safety, fairness, and privacy. He is the co-author of the newsletter STAT Health Tech. [email protected] @caseymross Tags finance medical technology STAT+ Create a display name to comment This name will appear with your comment [ ] There was an error saving your display name. Please check and try again. [Continue] Trending Knee x-ray Researching collagen to help his achy knees, a statistician... Researching collagen to help his achy knees, a statistician explores the painfully weak evidence [] New data show those who recovered from Covid-19 were... New data show those who recovered from Covid-19 were less likely than vaccinated to get infected... Epstein-Barr virus Strong new evidence suggests a virus triggers multiple sclerosis Strong new evidence suggests a virus triggers multiple sclerosis Recommended Watson on laptop The sale of Watson Health assets ends a dark... The sale of Watson Health assets ends a dark chapter for IBM. For its buyer, the... Pharmalot Coming/Going STILL Up and down the ladder: The latest comings and... Up and down the ladder: The latest comings and goings [] Pharmalittle: Alzheimer's patient groups to protest Medicare plan for... Pharmalittle: Alzheimer's patient groups to protest Medicare plan for Biogen drug; cancer combo treatments are questioned Recommended Stories Watson on laptop Health Tech The sale of Watson Health assets ends a dark chapter for IBM. For its buyer, the opportunity looks brighter By Casey Ross [330x400-00] Health Tech For doctors drowning in emails, one health system's new strategy: pay for replies By Mohana Ravindranath advertisement mental health app use Health Tech What types of mental health apps actually work? A sweeping new analysis finds the data is sparse By Mario Aguilar [330x400-00] Biotech With $3 billion, Hal Barron and other biotech veterans launch a disease 'reversal' company By Matthew Herper [330x400-00] Health Tech Wary of a backlash, telehealth startups focused on women's sexual health steer clear of abortion pills By Olivia Goldhill STAT Reporting from the frontiers of health and medicine Trending: * First Opinion * Coronavirus * Health * Biotech * Matt's Take * Health Tech Back to top Company * About STAT * Awards * Contact Us * Careers & Internships * Contribute * Diversity & Inclusion * Licensing Stories * Our Team Account * About STAT+ * FAQs * Log In * Subscribe App & Other Products * STAT App * Newsletters * Podcasts * STAT Madness * STAT Reports * STAT Trials Pulse * STAT Wunderkinds Group Subscriptions * Contact Us * Request A Quote Advertising * Advertise With Us * Download Media Kit Events * Industry Events Calendar * STAT Events * STAT Summits * Sponsor An Event * Privacy * Comment Policy * Terms * Do Not Sell my Data * (c)2022 STAT * * * * * * *